[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regenxbio Inc (RGNX)

Regenxbio Inc (RGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 707,659
  • Shares Outstanding, K 66,013
  • Annual Sales, $ 170,440 K
  • Annual Income, $ -193,880 K
  • EBIT $ -164 M
  • EBITDA $ -149 M
  • 60-Month Beta 0.94
  • Price/Sales 4.28
  • Price/Cash Flow N/A
  • Price/Book 8.35

Options Overview Details

View History
  • Implied Volatility 113.88% (-8.03%)
  • Historical Volatility 107.91%
  • IV Percentile 21%
  • IV Rank 11.96%
  • IV High 483.38% on 09/23/25
  • IV Low 63.68% on 09/05/25
  • Expected Move (DTE 25) 1.23 (15.29%)
  • Put/Call Vol Ratio 1.71
  • Today's Volume 3,208
  • Volume Avg (30-Day) 454
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 5,363
  • Open Int (30-Day) 8,533
  • Expected Range 6.83 to 9.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.36
  • Number of Estimates 5
  • High Estimate $-1.20
  • Low Estimate $-1.63
  • Prior Year $-1.20
  • Growth Rate Est. (year over year) -13.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.77 +3.73%
on 08/24/26
12.08 -33.28%
on 08/20/26
-1.67 (-17.16%)
since 07/24/26
3-Month
5.88 +37.07%
on 06/11/26
15.88 -49.24%
on 07/08/26
+1.71 (+26.93%)
since 05/22/26
52-Week
5.45 +47.75%
on 05/18/26
16.19 -50.22%
on 01/22/26
-0.95 (-10.54%)
since 08/22/25

Most Recent Stories

More News
Stock Indices Finish Mostly Lower on Chipmaker Weakness

The S&P 500 Index ($SPX ) (SPY ) closed down by -0.28% on Monday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +0.26%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.97%. ...

SAIA : 349.54 (-3.48%)
AVGO : 358.76 (-2.63%)
SNDK : 1,493.12 (-6.45%)
CVX : 203.09 (-1.06%)
EXPE : 339.13 (+5.44%)
TXN : 258.94 (-2.05%)
FDXF : 131.27 (-4.41%)
$IUXX : 29,023.18 (-0.97%)
ARCB : 134.45 (-4.20%)
ZNU26 : 108-145 (unch)
OXY : 60.11 (-1.94%)
ESU26 : 7,673.50 (+0.05%)
Rout in Chipmakers Weighs on Broader Market

The S&P 500 Index ($SPX ) (SPY ) is down by -0.27% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.26%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -1.00%. E-mini S&P futures...

AMAT : 484.19 (-1.65%)
SNDK : 1,493.12 (-6.45%)
CVX : 203.09 (-1.06%)
DHI : 148.97 (+0.42%)
BLDR : 70.22 (+0.01%)
SLB : 54.00 (+0.24%)
TXN : 258.94 (-2.05%)
$IUXX : 29,023.18 (-0.97%)
ZNU26 : 108-145 (unch)
KBH : 55.64 (+0.49%)
OXY : 60.11 (-1.94%)
ESU26 : 7,673.50 (+0.05%)
Stocks Pressured by Weakness in Chipmakers and AI-Infrastructure Stocks

The S&P 500 Index ($SPX ) (SPY ) is down by -0.43% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.19%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -1.41%. E-mini S&P futures...

AMAT : 484.19 (-1.65%)
SNDK : 1,493.12 (-6.45%)
DHI : 148.97 (+0.42%)
BLDR : 70.22 (+0.01%)
$IUXX : 29,023.18 (-0.97%)
ZNU26 : 108-145 (unch)
KBH : 55.64 (+0.49%)
ESU26 : 7,673.50 (+0.05%)
PHM : 129.61 (+0.47%)
MA : 599.86 (+3.31%)
STX : 794.65 (-6.51%)
V : 382.41 (+3.06%)
Regenxbio: Q2 Earnings Snapshot

Regenxbio: Q2 Earnings Snapshot

RGNX : 8.06 (-24.81%)
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

ROCKVILLE, Md. , Aug. 6, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the second quarter ended June 30, 2026.

RGNX : 8.06 (-24.81%)
REGENXBIO's Pivotal Duchenne Data Casts a Shadow Over Tomorrow's Cash Runway Disclosure

Barchart Research What to Expect from RGNX Earnings RGNX Generated August 5, 2026 Current Price $10.50 EPS Estimate $$0.12 Consensus Rating Moderate Buy Average Move 8.79% REGENXBIO's Pivotal Duchenne...

RGNX : 8.06 (-24.81%)
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights

ROCKVILLE, Md. , Aug. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 6, at 8:00 a.m. ET to discuss its financial results...

RGNX : 8.06 (-24.81%)
Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm

NEW YORK , July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regenxbio, Inc. (NASDAQ: RGNX) ...

RGNX : 8.06 (-24.81%)
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

ROCKVILLE, Md., , July 18, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive data from long-term follow-up studies of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314)...

RGNX : 8.06 (-24.81%)
REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

ROCKVILLE, Md. , July 17, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the pricing of an underwritten public offering of 10,003,889 shares of its common stock at the price of $9.00 per...

RGNX : 8.06 (-24.81%)

Business Summary

REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver...

See More

Key Turning Points

3rd Resistance Point 9.41
2nd Resistance Point 9.03
1st Resistance Point 8.54
Last Price 8.06
1st Support Level 7.67
2nd Support Level 7.29
3rd Support Level 6.80

See More

52-Week High 16.19
Fibonacci 61.8% 12.09
Fibonacci 50% 10.82
Fibonacci 38.2% 9.56
Last Price 8.06
52-Week Low 5.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.